12/22/20

The 21 Best Stocks to Buy for 2021

12/18/20

Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

12/15/20

Silicon Ranch Closes $225 Million Equity Raise with Existing Shareholders

11/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

10/8/20

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma

10/6/20

PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab

9/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx-SCC

7/27/20

Mindera Corporation Announces Appointment of George W. Mahaffey as President and Chief Executive Officer

6/24/20

Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock

5/27/20

PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

1/13/20

PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

1/10/20

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® forPB2452

11/21/19

AN2 Therapeutics Launches with $12 Million in Series A Funding and Announces a Strategic Partnership with Brii Biosciences

11/19/19

Silicon Ranch signs on for 107-MW solar project for Facebook in Georgia

10/29/19

Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting

10/15/19

PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor

10/7/19

Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma

8/14/19

PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452

7/29/19

Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

6/26/19

Silicon Ranch Launches Regenerative Energy™

4/8/19

PhaseBio Announces Closing of Public Offering of Common Stock

4/8/19

PhaseBio Receives Breakthrough Therapy Designation

3/19/19

Applied LifeSciences & Systems Announces Closing of its $8 Million Series A Round of Equity Financing

3/17/19

Full Results from PhaseBio Phase I Clinical Trial Published in New England Journal of Medicine

3/6/19

Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction

2/7/19

Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck

1/30/19

Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions

1/7/19

Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study

12/6/18

Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to its Board of Directors

12/5/18

Silicon Ranch to Help Power Facebook Data Center in Georgia

10/18/18

Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma

8/27/18

PhaseBio Secures $34 Million in Series D Financing

7/30/18

Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis

6/28/18

APPELLO COMPLETES $10.5 MILLION SERIES A FINANCING LED BY DEERFIELD MANAGEMENT AND MOUNTAIN GROUP PARTNERS

3/28/18

Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma

1/22/18

Shell Takes a Major Stake in US Solar Developer Silicon Ranch

1/22/18

Shell Acquires Interest in Silicon Ranch Corporation

1/4/18

AgTech Accelerator Launches First Investment in Novel Fungicide Company, Boragen Inc., with $10 Million Series A Financing